Lawrence D. Kaplan, MD
Several treatment questions remain following data from recent clinical trials in Hodgkin lymphoma, mantle cell lymphoma (MCL), and follicular lymphoma (FL), explained Lawrence D. Kaplan, MD.
According to findings from the phase III ECHELON-1 trial, brentuximab vedotin (Adcetris) combined with doxorubicin, vinblastine, and dacarbazine (A+AVD) has shown significant activity in patients with advanced Hodgkin lymphoma.
The initial results of the global study indicated a 5.1% benefit with A+AVD in 2-year modified progression-free survival (mPFS) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). A subgroup analysis of the North American population revealed an absolute difference of 10.6% in mPFS per independent review facility and an 11.7% difference in PFS per investigator review at 2 years.
... to read the full story